Struggling to find Abrilada at your pharmacy? Learn why this Humira biosimilar can be hard to locate in 2026 and what you can do to get your prescription filled.
You got your prescription for Abrilada, called your pharmacy, and heard the words no patient wants to hear: "We don't have it in stock." If that's happened to you, take a breath — you're not the only one dealing with this. Thousands of patients across the country have run into the same problem trying to fill their Abrilada prescriptions in 2026.
Abrilada (Adalimumab-afzb) is a biologic medication made by Pfizer. It's an interchangeable biosimilar to Humira, one of the most widely prescribed drugs in the world. That means it works the same way, treats the same conditions, and can be substituted at the pharmacy without needing a new prescription from your doctor.
So why is it so hard to find? Let's break it down.
Abrilada belongs to a class of drugs called TNF alfa inhibitors. It works by blocking a protein called tumor necrosis factor alpha (TNF-alpha) that causes inflammation in your body. By reducing this inflammation, Abrilada helps manage symptoms of several chronic autoimmune conditions.
Abrilada is FDA-approved to treat:
If you'd like a deeper look at how this medication works, check out our guide on how Abrilada works.
There are several reasons you might be struggling to locate Abrilada at your local pharmacy. Here are the main ones:
Unlike common medications like blood pressure pills or antibiotics, Abrilada is a specialty biologic. That means most regular retail pharmacies — your local CVS, Walgreens, or grocery store pharmacy — don't typically stock it on their shelves.
Biologic medications like Abrilada require special handling, including cold storage and careful shipping. They're usually dispensed through specialty pharmacies that have the infrastructure to store and ship these temperature-sensitive drugs. If you're trying to find Abrilada at a regular retail pharmacy, that's likely why you're coming up empty.
Here's where things get complicated. Even though Abrilada is an interchangeable biosimilar to Humira, not every insurance plan covers it. Insurance companies negotiate deals with drug manufacturers, and they may prefer a different adalimumab biosimilar on their formulary.
There are now 10+ adalimumab biosimilars on the market — including Cyltezo, Hadlima, Hyrimoz, Amjevita, and others. Your insurance company may steer you toward whichever product they've negotiated the best price for. This can make it harder for pharmacies to justify stocking Abrilada if most of their patients are being directed to a different biosimilar.
The adalimumab biosimilar market has become one of the most competitive in pharmaceutical history. With so many options available, pharmacies and specialty distributors must decide which products to keep in inventory. No pharmacy can stock every biosimilar, so some — including Abrilada — may not be readily available at every location.
Even when a pharmacy has Abrilada, your insurance may require prior authorization before they'll cover it. This means your doctor needs to submit paperwork proving that Abrilada is medically necessary for your condition. This process can take days or even weeks, during which time you might feel like the drug is impossible to get.
Some plans also require step therapy, meaning you have to try (and fail on) other treatments like Methotrexate before they'll approve a biologic like Abrilada.
Don't give up. Here are some practical steps to help you get your Abrilada prescription filled:
The fastest way to find out which pharmacies near you have Abrilada in stock is to use Medfinder. It checks real-time availability so you don't have to call pharmacy after pharmacy yourself.
Your doctor's office likely works with one or more specialty pharmacies. Ask them which specialty pharmacy they recommend for Abrilada. Pfizer's enCompass program can also help connect you with a specialty pharmacy that carries the medication.
Call 1-844-722-6672 to reach Pfizer's enCompass support program. They can help with:
If you absolutely cannot find Abrilada, your doctor may be able to switch you to another adalimumab biosimilar that's more readily available through your insurance. Check out our post on alternatives to Abrilada for more details.
Independent pharmacies sometimes have more flexibility in what they order. If your local chain pharmacy doesn't stock Abrilada, an independent or compounding pharmacy in your area might be able to order it for you. For more tips, see our guide on how to find Abrilada in stock near you.
Cost is another factor that can make finding Abrilada feel difficult. Without insurance, Abrilada can cost around $2,050 to $3,530 per dose at retail pharmacies. However, Abrilada's wholesale list price is approximately $1,038 per dose — about 60% lower than Humira's list price — making it one of the more affordable adalimumab options available.
With the Pfizer enCompass Co-Pay Assistance Program, eligible commercially insured patients can reduce their out-of-pocket costs significantly. For more ways to save, read our guide on how to save money on Abrilada.
Finding Abrilada can feel frustrating, but understanding why it's hard to find puts you in a much better position to solve the problem. The specialty pharmacy distribution model, insurance formulary preferences, and a crowded biosimilar market all contribute to the challenge.
The good news? There are real solutions. Tools like Medfinder can help you locate Abrilada in stock, and Pfizer's support programs can help with both access and affordability. Don't hesitate to advocate for yourself — or ask your doctor's office to help.
You deserve access to the medication that keeps you feeling your best.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
